LanguaTalk

BioCentury This Week

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

Ep. 161 - New Cancer Paradigms, Distilling Innovations, & IPOs

17 mins; February 13, 2023

Ep. 160 - Dose Optimization, Clinical Trials Diversity and QALYs

25 mins; February 06, 2023

Ep. 159 - BIO's Priorities, ESG & Venture Trends

23 mins; January 30, 2023

Ep. 158 - CAR T Manufacturing & Orphan Drugs

29 mins; January 23, 2023

Ep. 157 - 2023 Markets Outlook & Buyside Picks

27 mins; January 17, 2023

Ep. 156 - JPM Highlights & Alzheimer's Takeaways

30 mins; January 09, 2023

Ep. 155 - U.K. Biotech, Aduhelm, 2022 Approval Trends

35 mins; January 03, 2023

Ep. 154 - Madrigal in NASH, Moderna & Neoantigens, the Distillery

19 mins; December 19, 2022

Ep. 153 - The Inflation Reduction Act

19 mins; December 19, 2022

Ep. 152 - Amgen's Horizon Takeout. Plus: ASH, SERDs

17 mins; December 12, 2022

Ep. 151 - Alzheimer's Takeaways, U.K. Biotech, Charles Forum

26 mins; December 05, 2022

Ep. 150 - Model Term Sheets, Pragmatic Trials & Gene Therapy Prices

18 mins; November 28, 2022

Ep. 149 - Takeaways from the East-West Summit

22 mins; November 21, 2022

Ep. 148 - East-West Summit Highlights Part 2

22 mins; November 18, 2022

Ep. 147 - East-West Summit Highlights Part 1

25 mins; November 16, 2022

Ep. 146 - What's Next in Washington, Plus: SITC & the Distillery

18 mins; November 14, 2022

Ep. 145 - What's Next for BIO, Plus: Pfizer, GSK

20 mins; November 07, 2022

Ep. 144 - Alnylam's IRA Pause, Plus Argenx & Accumulus

24 mins; October 31, 2022

Ep. 143 - East-West Summit Preview

24 mins; October 28, 2022

Ep. 142 - Lundbeck, Biogen, Biden & Biomanufacturing, Nora Volkow

26 mins; October 24, 2022

Ep. 141 - Neoantigen Vaccines, Drug Pricing, U.S.-China & U.K. Turmoil

25 mins; October 17, 2022

Ep. 140 - Turbulence at BIO, Plus 4Q Preview & the Distillery

29 mins; October 10, 2022

Ep. 139 - Wins in Neurodegeneration, U.S.-China & Life Science Cares

26 mins; October 03, 2022

Ep. 138 - FDA User Fee Endgame, East-West Summit & Biogen

27 mins; September 26, 2022

Ep. 137 - Intellia's Data, IRA's Orphan Impact, CFIUS Order

18 mins; September 19, 2022

Ep. 136 - IRA, KRAS & ESMO

22 mins; September 12, 2022

Ep 135 Pt. 5 - A Portrait of Biopharma's New Leaders

19 mins; September 02, 2022

Ep 135 Pt. 4 - Filling Biopharma's Talent Pipeline

16 mins; September 01, 2022

Ep 135 Pt. 3 - Rising Leaders & the VC View on Talent

16 mins; August 31, 2022

Ep 135 Pt. 2 - CEOs in the Spotlight. Plus: Women Leaders, DEI

18 mins; August 30, 2022

Ep 135 Pt. 1 - Back to School 2022 Overview

16 mins; August 29, 2022

Ep. 134 - Preclinical Deal Making, Bluebird's Approval & Epigenome Editing

19 mins; August 22, 2022

Ep. 133 - Financing Thaw? Plus: Protein Design & China Audits

19 mins; August 15, 2022

Ep. 132 - M&A & Data: recipe for a rebound?

19 mins; August 08, 2022

Ep. 131 - Seagen, New Modalities & Structure

17 mins; August 01, 2022

Ep. 130 - Steady as a Roche. Plus: Washington Turbulence

19 mins; July 25, 2022

Ep. 129 - Burr Bill, Novartis Makeover, ALS Update

21 mins; July 18, 2022

Ep. 128 - Financial Markets Forecast, AAV Toxicity & Drug Pricing

23 mins; July 11, 2022

Ep. 127 - TeneoTwo, Lightspeed, Arch & The Distillery

29 mins; July 05, 2022

Ep. 126 - Growing Galapagos, Plus Abortion & Biopharma

25 mins; June 27, 2022

Ep. 125 - Next Steps for ARPA-H

24 mins; June 20, 2022

Ep. 124 - CRISPR's High Bar, Private Equity Inroads and the Distillery

27 mins; June 13, 2022

Ep. 123 - Fixing FDA's Broken Advisory Panels

20 mins; June 08, 2022

Ep. 122 - ASCO's Advances & Fixes for FDA's AdComms

26 mins; June 06, 2022

Ep. 121 - ASCO, CRISPR IP & CStone

22 mins; May 31, 2022

Ep. 120 - Next-gen NK cells, Plus Woodcock & BMS’s Russian Withdrawal

21 mins; May 23, 2022

Ep. 119 - Bio€quity Recap, Part 2

20 mins; May 18, 2022

Ep. 118 - Bio€quity Recap, Part 1

22 mins; May 17, 2022

Ep. 117 - Sofinnova Partners’ Growth Deal, Plus Distillery on Tap

22 mins; May 16, 2022

Ep. 116 - The Road to Bio€quity 2022: Navigating Through Talent & Capital Headwinds

22 mins; May 12, 2022

Ep. 115 - FDA Reform on Deck, Plus Translation at Howard

18 mins; May 09, 2022

Ep. 114 - Hutchmed Setback, FDA in Focus, HilleVax's IPO

21 mins; May 02, 2022

Ep. 113 - Nkarta’s Breakthrough, Hatch’s Legacy & Shanghai’s Lockdown

20 mins; April 25, 2022

Ep. 112 - Digesting DDR Data; Plus Sharpless’ Legacy, McKinsey’s Conflicts

20 mins; April 18, 2022

Ep. 111 - Seeking Green Shoots Amid Biotech’s Gloom

17 mins; April 14, 2022

Ep. 110 - Aduhelm’s Lessons, Plus Distillery Discoveries, Rare Disease Innovation

23 mins; April 11, 2022

Ep. 109 - What's Next for Novartis? Plus: AACR, Merck KGaA

20 mins; April 04, 2022

Ep. 108 - AACR Preview for CAR Ts in Solid Tumors; Plus FDA Weighs in on Data for ALS Ad Com

19 mins; March 28, 2022

Ep. 107 - A Tale of Two Targets: LAG3, IL-2; Plus Alternatives to Cash Up

20 mins; March 21, 2022

Ep. 106 - China's C-suite Hears FDA, Plus AACR, ARPA-H

21 mins; March 14, 2022

Ep. 105 - War Pulls Biotech to Ukraine, Out of Russia

22 mins; March 07, 2022

Ep. 104 - Biotech Shows Support for Ukraine, Plus Latest Intellia Data

22 mins; February 28, 2022

Ep. 103 - Califf’s Priorities for Second Stint as FDA Commissioner

22 mins; February 22, 2022

Ep. 102 - What FDA's Tyvyt Precedent Means for China; plus Translational Trendspotting

20 mins; February 14, 2022

Ep. 101 - Of Biotech Bears, Pazdur & PDUFA

28 mins; February 07, 2022

Ep. 100 - Capital markets check in; plus Belgium’s prodigal son returns

26 mins; January 31, 2022

Ep. 99 - Introducing The BioCentury Show, Plus Califf, COVID and GSK

26 mins; January 24, 2022

Ep. 98 - Bargain Hunting in a Rocky Market, plus Advantage, CMS

23 mins; January 18, 2022

Ep. 97 - Buysiders' Picks, plus JPM22 roundup

27 mins; January 10, 2022

Ep. 96 - Aduhelm, Pazdur, Pharma Digital & '21 Wrap

23 mins; December 20, 2021

Ep. 95 - ASH's New Targets, Avistone & Washington Update

19 mins; December 13, 2021

Ep. 94 - Woodcock's To-Do List, Maraganore's Takeaways & the Distillery

22 mins; December 06, 2021

Ep. 93 - Omicron's Open Questions, Plus the Business Case for Ultra-rare Diseases

19 mins; November 29, 2021

Ep. 92 - Biogen’s R&D decision, previewing TIGIT & China Summit highlights

23 mins; November 22, 2021

Ep. 91 - China Summit Highlights: Day 2

38 mins; November 17, 2021

Ep. 90 - China Summit Highlights: Day 1

36 mins; November 17, 2021

Ep. 89 - Califf's Passions, RWE in China & LSP Rising

32 mins; November 15, 2021

Ep. 88 - China Summit Preview: The Bridge to Innovation

28 mins; November 10, 2021

Ep. 87 - Digesting Drug Pricing, Plus Access in ALS

32 mins; November 08, 2021

Ep. 86 - Woodcock's Legacy, Plus Frazier, Bain & the Distillery

26 mins; November 01, 2021

Ep. 85 - What's Next for CRISPR & Gene Therapy, Plus China Summit Preview

23 mins; October 25, 2021

Ep. 84 - Why Gene Therapy's Bad Year Is a Speed Bump, Not a Dead End

23 mins; October 21, 2021

Ep. 83 - Assessing Biogen’s ALS Miss, Plus Califf on Deck

23 mins; October 18, 2021

Ep. 82 - 4Q Markets Preview, Plus the Future of NIH

30 mins; October 11, 2021

Ep. 81 - Merck & the State of M&A, Plus Novartis CEO's Call to Action

22 mins; October 04, 2021

Ep. 80 - Hong Kong Rising, Plus Varmus' POV & Biden's FDA Choice

27 mins; September 27, 2021

Ep. 79 - ESMO, Jeito & the Latest from Washington

23 mins; September 20, 2021

Ep. 78 - Remembering Fred Frank, Lisa Raines, Plus CRISPR, Washington Updates

27 mins; September 13, 2021

Ep. 77 - Back to School Spotlight & Pressures on FDA

22 mins; September 03, 2021

Ep 76 Pt. 4 - Modifying Access for Accelerated Approvals

13 mins; September 01, 2021

Ep 76 Pt. 3 - Delivering the Evidence for Accelerated Approval

14 mins; August 31, 2021

Ep 76 Pt. 2 - Standards of Evidence for Accelerated Approval

14 mins; August 30, 2021

Ep 76 Pt. 1 - Accelerated Approval's Big Picture

22 mins; August 30, 2021

Ep. 75 - Back to School Preview, plus Pfizer Eats Trillium

22 mins; August 23, 2021

Ep. 74 - Vertex's Road Map & Innovation in MS

13 mins; August 16, 2021

Ep. 73 - Next Up in COVID with Otello Stampacchia and Umer Raffat

19 mins; August 12, 2021

Ep. 72 - Modality Matters: M&A Heats Up, Galbraith Maps AZ's BD

18 mins; August 09, 2021

Ep. 71 - Lessons from China’s Market Turmoil, Plus Distillery on Tap

27 mins; August 02, 2021

Ep. 70 - Prepping for China’s IP law with Jones Day’s Tony Chen

17 mins; July 29, 2021

Ep. 69 - Allaying Aduhelm Concerns, Plus Master Protocols, Arvinas-Pfizer

14 mins; July 26, 2021

Click here to see more

BioCentury This Week

Useful pages

Find a tutor

Languages